Literature DB >> 15546288

Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to intervention.

Jürgen Haase1, Rusen Bayar, Matthias Hackenbroch, Hans Störger, Manfred Hofmann, Claus-Eberhard Schwarz, Harald Reinemer, Franz Schwarz, Johannes Ruef, Torsten Sommer.   

Abstract

BACKGROUND: The quantitative assessment of myocardial infarctions using delayed contrast-enhanced magnetic resonance imaging (MRI) has recently been validated using postmortem histopathological animal studies. In a prospective study, we investigated the correlation between infarct size as assessed by delayed contrast-enhanced MRI, elevation of creatine kinase (CK), and c-reactive protein (CRP) as well as the time from onset of symptoms to intervention.
METHODS: Four to 10 days after immediate PCI in 45 acute ST-segment elevation myocardial infarction (STEMI) patients (<24 hour) with stenting of the infarct-related artery and treatment with abciximab, we performed gadolinium contrast-enhanced three-dimensional inversion recovery gradient-echo MR sequences with complete coverage of the LV-myocardium in short-axis slices. The mass of infarcted tissue based on the volume of hyperenhanced myocardium was calculated and linear regression analysis was performed to assess the correlation between absolute size of infarctions (g) as well as relative size (LV%) with peak values of CK, CRP, and the time to PCI.
RESULTS: There was a significant correlation between absolute size of infarctions (g) and peak CK values (r = 0.72; P < 0.001) as well as the relative size (LV%) and peak CK (r = 0.77; P < 0.001). No correlations were found between absolute size (r = 0.33) as well as relative size (r = 0.27) of infarctions and peak CRP. There was also no correlation between absolute (r = 0.29) as well as relative size of infarctions (r = 0.27) and the time from onset of symptoms to PCI.
CONCLUSIONS: In patients with acute STEMI (<24 hour) undergoing immediate PCI with stenting and treatment with abciximab, peak CK values correlated well with infarct size as assessed by delayed contrast-enhanced MRI. There were no correlations between infarct size and peak CRP as well as the time to intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546288     DOI: 10.1111/j.1540-8183.2004.04078.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  11 in total

Review 1.  Contrast agents and cardiac MR imaging of myocardial ischemia: from bench to bedside.

Authors:  Pierre Croisille; Didier Revel; Maythem Saeed
Journal:  Eur Radiol       Date:  2006-04-22       Impact factor: 5.315

2.  Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI.

Authors:  Gert Klug; Agnes Mayr; Johannes Mair; Michael Schocke; Michael Nocker; Thomas Trieb; Werner Jaschke; Otmar Pachinger; Bernhard Metzler
Journal:  Clin Res Cardiol       Date:  2011-01-04       Impact factor: 5.460

3.  Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction.

Authors:  Ronald Reiter; Cory Swingen; Luke Moore; Timothy D Henry; Jay H Traverse
Journal:  Circ Res       Date:  2011-11-17       Impact factor: 17.367

4.  Preinfarction angina reduces infarct size in ST-elevation myocardial infarction treated with percutaneous coronary intervention.

Authors:  Ronald Reiter; Timothy D Henry; Jay H Traverse
Journal:  Circ Cardiovasc Interv       Date:  2013-01-22       Impact factor: 6.546

5.  Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction.

Authors:  Iwona Swiatkiewicz; Marek Kozinski; Przemyslaw Magielski; Tomasz Fabiszak; Adam Sukiennik; Eliano Pio Navarese; Grazyna Odrowaz-Sypniewska; Jacek Kubica
Journal:  Mediators Inflamm       Date:  2012-09-02       Impact factor: 4.711

6.  Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI.

Authors:  Tim Tödt; Eva Maret; Joakim Alfredsson; Magnus Janzon; Jan Engvall; Eva Swahn
Journal:  BMC Cardiovasc Disord       Date:  2012-02-23       Impact factor: 2.298

7.  Magnetic resonance imaging in interventional therapy of patients with acute myocardial infarction prior to and after treatment.

Authors:  Yuzhou Li; Chunrong Li; Hongrui Jin; Wenqi Huang
Journal:  Exp Ther Med       Date:  2016-07-21       Impact factor: 2.447

8.  Infarct evolution in man studied in patients with first-time coronary occlusion in comparison to different species - implications for assessment of myocardial salvage.

Authors:  Erik Hedström; Henrik Engblom; Fredrik Frogner; Karin Aström-Olsson; Hans Ohlin; Stefan Jovinge; Håkan Arheden
Journal:  J Cardiovasc Magn Reson       Date:  2009-09-23       Impact factor: 5.364

9.  A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study.

Authors:  Benjamin Hibbert; Ronnen Maze; Ali Pourdjabbar; Trevor Simard; F Daniel Ramirez; Rohit Moudgil; Melissa Blondeau; Marino Labinaz; Alexander Dick; Christopher Glover; Michael Froeschl; Jean-François Marquis; Derek Y F So; Michel R Le May
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

10.  C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes.

Authors:  Hadeel Alkofide; Gordon S Huggins; Joni R Beshansky; Robin Ruthazer; Inga Peter; Madhab Ray; Jayanta T Mukherjee; Harry P Selker
Journal:  BMC Cardiovasc Disord       Date:  2015-12-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.